HI
LXRX icon

HBK Investments’s Lexicon Pharmaceuticals LXRX Stock Holding History

HBK Investments’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-42,400
Closed -$608K – 974
2017
Q1 		$608K Buy
+42,400
New +$629K ﹤0.01% 486
2016
Q4 		– Sell
-69,900
Closed -$1.26M – 815
2016
Q3 		$1.26M Buy
+69,900
New +$1.12M 0.01% 464

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $27.8B AUM 39.42% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HBK Investments's LXRX Position: Q2 2017 in Review

HBK Investments sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 42,400 shares — an estimated $608K sold.

HBK Investments first reported a position in LXRX in Q3 2016 and held it in 2 quarters. The position peaked at $1.26M in Q3 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

  • HBK Investments reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • HBK Investments sold 42,400 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $608K.
  • HBK Investments first reported a position in Lexicon Pharmaceuticals in Q3 2016 and held it in 2 quarters.
  • HBK Investments's Lexicon Pharmaceuticals position peaked at $1.26M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on HBK Investments's 13F filing for Q2 2017, filed 14 Aug 2017.